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Abstract 
Valproic acid (VPA) is a wide spectrum antiepileptic medication indicated for seizure prophylaxis 
across the spectrum of epilepsy. Since coming into clinical use, VPA has also been recommended for 
the management of a variety of other pathologies, including, most notably, mood stabilization in the 
manic patient. 
VPA’s common adverse effects include gastrointestinal, influenza-like symptoms, headache, and 
difficulties with sleep; nonetheless, in rare instances, VPA has been noted to cause the severe and 
potentially lethal condition of hyperammonemia with encephalopathy (VIHE). 
VIHE is the result of a dose-independent increase in ammonia levels. Often the patient is 
asymptomatic; if symptoms reach clinical threshold, lethargy is most common, though seizures, focal 
neurologic deficits and even coma are possible. VIHE can occur in patients despite normal hepatic 
function, normal loading doses, chronic stable doses and normal free serum drug levels. Once the 
diagnosis is confirmed, the first approach for symptomatic patients is to discontinue VPA, start 
alternative mood stabilizer as indicated, and supplement hyperammonemia treatment with lactulose, 
carnitine or carglumic acid. Below is a case report of VIHE that developed in an adolescent girl with a 
history of Bipolar I Disorder who was hospitalized in our facility for stabilization of mania.  As 
demonstrated below, early diagnosis of VIHE is pivotal in reducing morbidity and ultimately can be 
life-saving. 
Keywords: Valproic acid, Hyperammonemia, Encephalopathy. 
Introduction 
VPA is an FDA approved antiepileptic medication and mood stabilizer indicated for a variety of uses, 
including partial seizures, complex seizures absence seizures and acute stabilization of mania. VPA is 
well known for a variety of side effects ranging from hair loss, weight gain, anorexia, to more severe 
complications such as hepatotoxicity, thrombocytopenia, and teratogenicity. Amongst the more rare 
and idiosyncratic adverse effects that should remain on the clinician’s differential is Valproic Acid 
Induced Hyperammonemia with Encephalopathy (VIHE), which consists of an elevated serum 
ammonia presenting with neurocognitive and behavioral changes [1,2]. Hyperammonemia due to 
Valproic Acid is mostly asymptomatic, but when symptomatic can be severe and deadly. Lethargy and 
somnolence are the common presentations of VIHE, but other symptoms can range from confusion, 
delirium, seizures, coma, and death [3]. We recommend that physicians should consider the diagnosis 
of VIHE with any alteration in mental status following VPA use and early diagnosis can effectively lower 
mortality. Below is described a clinical case of VIHE manifested by lethargy and somnolence and 
diagnosed by ammonia and drug levels.  
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Case report 
This is the case of a 17-year-old African American girl with one-year history of Bipolar I Disorder who 
was initially hospitalized for stabilization of a mixed mood episode, manifested by low mood, 
hypersexual behavior, and grandiose delusions. Furthermore, she was prone to dissociative episodes 
and psychotically agitated behavior. It is thought this episode was precipitated by her discontinuation 
of outpatient medications (Lithium carbonate 900 mg, twice daily and Quetiapine 500 mg nightly), 
which she reported were too sedating. 
Medications were reconciled in the hospital and lithium resumed at 600mg qAM / 900mg qHS for 
mood stabilization and Seroquel restarted at 200mg qAM / 300mg qHS for psychosis. She was kept 
under close observation for disorganization, agitation, and sexually provocative behavior. Although 
lithium levels were closely followed still on day 3 she began to complain of GI upset and diarrhea. 
Lithium serum levels were evaluated that showed abnormally high levels, prompting its 
discontinuation. The patient quickly decompensated without the mood stabilizing medication, 
demonstrated by sexually provocative behavior, pressured speech and easy distractibility. Thus, 
decision was made to start VPA at 500mg daily in the morning and 1000 mg nightly, 
After 3 days of treatment with VPA, the patient began to appear confused, lethargic, and to ambulate 
with poor gait and balance. STAT VPA and ammonia levels were assessed and found to be 130 (normal 
range 50-120µmol/L) and 84 (normal range 11-35µmol/L) respectively. Neurologic exam revealed 
intact cranial nerves, the absence of focal neurologic deficits, MMSE was performed to know the 
mental status that was found to be 22/30 (normal >24/30). Further studies include CBC, 
BUN/creatinine, serum bilirubin, LFT, electrolyte panel and glucose and calcium levels. CBC revealed 
high MCV and low hemoglobin suggesting folic acid deficiency. Both Seroquel and VPA were 
discontinued, and folic acid added for treating the macrocytic anemia. 
Following discontinuation of VPA, ammonia levels dropped from 84 to 42(normal range 11-35µmol/L) 
by the end of that day. On hospital, day 8, cognition returned to baseline, but problematic manic 
symptoms re-emerged, ultimately prompting a trial of haloperidol 10mg daily. With still inadequate 
response to haloperidol monotherapy, resumption of VPA was deemed clinically necessary on day 15, 
with serum levels of VPA and ammonia both found to be within normal limits. Approximately one 
week later, she was determined to be at baseline mental status, clinically stable and fit for discharge. 
Psychoeducation provided to patient and family regarding reoccurrence of VIHE and notable signs and 
symptoms with instructions to return to the hospital. 
Discussion 
The symptoms of hyperammonemia are quite difficult to be recognized in psychiatric patients. It is 
suggested that patients taking valproic acid should be closely monitored for mental status changes, 
delirium, confusion, focal neurologic deficits and this monitoring can detect an early VIHE [2]. Ammonia 
levels and drug levels should be checked immediately if a patient develops lethargy or any neurological 
symptoms. Ammonia levels are best monitored in the blood, while VPA levels can be best monitored 
in saliva, so both levels are closely checked timely [4]. 
Moreover rising ammonia levels most of the times is correlated with high serum levels of the drug as 
suggested in a trial [5]. Although, as we have observed, VPA levels may be normal in suspected VIHE 
cases, which suggests the need for close monitoring of ammonia levels in patients with VPA 
prescription. Once the diagnosis is made for VIHE, next best step is to discontinue VPA and add 
alternative medication for psychiatric symptoms, addition for hyperammonemia treatment including 
lactulose, carnitine or carglumic acid has shown significant results in lowering ammonia level and 
associated symptoms [6-8]. We have also reviewed a clinical trial in which 40 participants were 
prescribed a loading dose of valproic acid, and among them, 30 participants developed an increase in 
ammonia levels within one hour of infusion of VPA. Serum ammonia and VPA levels were measured 
at baseline, one hour, and 24 hours after the administration. It was concluded that hyperammonemia 
was not associated with alteration in consciousness or hepatic transaminases, which was surprising 
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.The multivariable repeated analysis also shows lack of influence of VPA dose, VPA levels, infusion rate 
and gender on ammonia levels [9].  
Pharmacodynamics 
Valproic acid is a branched, medium chain fatty acid that undergoes mitochondrial beta-oxidation in 
the liver and is converted into toxic metabolite valproyl Co-A. This metabolite depletes the N-acetyl 
glutamate by inhibition of N-acetyl Glutamate synthetase N-acetyl glutamate is a cofactor for urea 
cycle rate-limiting enzyme carbamoyl phosphate synthetase (CPS 1) [10]. Depletion of N- acetyl 
glutamate results in inhibition of CPS 1, the rate-limiting enzyme of the urea cycle. This inhibition 
blocks the conversion of ammonia to urea leading to rising in ammonia levels.  
Conclusion 
Hyperammonemia with encephalopathy is a rare side effect of valproic acid toxication that carries a 
risk of high mortality. Rising ammonia levels can be asymptomatic most of the time but may give rise 
to symptoms ranging from mild confusion to coma and death. We conclude that valproic acid should 
be stopped immediately with the increase in ammonia levels in patients taking valproic acid, and 
lactulose with or without carnitine should be added to the treatment regimen. Patient medication 
lists should be reviewed for drug interactions causing high ammonia. Doctors prescribing valproic acid 
should have a high index of suspicion of VIHE and should closely monitor the mental status in patients 
taking valproic acid to reduce mortality. 
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